Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company specializing in the efficient large-scale production of proteins for human health and other non-pharmaceutical applications such as food, industrial, and wellness markets, provided an update on its business development efforts related to its Alternative Proteins division. Additionally, Dyadic highlighted emerging interest in applying its C1 platform in the diagnostic and vaccine space to address various infectious diseases, including the ongoing H5N1 outbreak. The Company also confirmed its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, beginning January 13, 2025.
“At Dyadic, we remain focused on using our innovative C1 and Dapibus™ protein production platforms to tackle key challenges in health, food technology, and industrial biotechnology,” said Mark Emalfarb, Dyadic’s Chief Executive Officer. “Throughout 2024, our primary emphasis has been on scaling the production and monetization of alternative proteins, presenting a significant and sustainable revenue stream. We will continue this strategic focus in 2025 as our partners prepare for multiple product launches in the Alternative Proteins sector. Furthermore, we have observed renewed interest from various industries in utilizing our C1 platform for diagnostics and vaccine development. This is evidenced by our recently secured $3 million grant from the Bill & Melinda Gates Foundation, supporting projects on RSV and Malaria, as well as collaborations with ViroVax LLC and other industry partners for diagnostic and therapeutic applications. As we approach key product launches and deepen engagement with global partners, we look forward to delivering innovative solutions to pressing global health issues.”
Alternative Proteins
Cell Culture Media
- Human Serum Albumin: In collaboration with Proliant Health and Biologicals, Dyadic is working toward a mid-2025 launch of Human Serum Albumin, a critical cell culture media component. Additionally, Dyadic anticipates reaching a third milestone related to productivity improvements (totaling $500,000) in the first half of 2025.
- Transferrin: Recombinant transferrin offers a consistent, animal-free solution to replace serum-derived transferrin, minimizing variability and contamination risks. Dyadic is currently engaging with prospective partners, supplying samples, and conducting additional testing to support its commercialization.
Non-Dairy Proteins
- Dairy Enzymes: A recombinant enzyme for cheese production, developed using Dyadic’s Dapibus™ platform, is nearing launch readiness and is expected to debut in 2025. Additional enzymes are under development.
- Alpha-Lactalbumin: Sampling is ongoing with interested companies in the food and reagent sectors. Dyadic is optimizing production and evaluating potential launch strategies.
Reagent Proteins
- DNA-RNA Enzyme Products: Dyadic has successfully developed a high-purity, scalable DNase 1 enzyme (RNase-Free) for applications in molecular diagnostics, biopharma, and other industries. Additionally, the Company has stable prototypes of four additional DNA/RNA manipulation products, including RNase Inhibitors and T7 RNA Polymerase.
Diagnostic and Vaccine Development
Dyadic’s collaborations with ViroVax LLC have led to the development of C1-produced antigens and vaccine candidates for multiple infectious diseases. The most notable progress includes:
- H5 Antigen Vaccine Candidate: A self-assembling ferritin nanoparticle vaccine candidate, produced using Dyadic’s C1 platform, has shown cross-protection against multiple H5 virus strains in preclinical studies.
- Mpox (Monkeypox) Antigen: Preclinical studies for a C1-produced Mpox antigen began in Q4 2024, supporting potential diagnostic and vaccine applications.
- Diagnostic Studies: Early studies using C1-produced antigens have shown promise in generating neutralizing antibodies, suggesting potential applications in both diagnostics and therapeutics.
J.P. Morgan Healthcare Conference
Dyadic’s management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, taking place January 13–16, 2025.
If you wish to schedule a meeting, please contact Dyadic at [email protected].
About Dyadic International, Inc.
Dyadic International, Inc. is a biotechnology company committed to large-scale, cost-effective protein production for use in health, nutrition, wellness, and industrial applications. The Company’s platforms, based on the C1 fungus (Thermothelomyces heterothallica), are designed to accelerate development timelines, lower costs, and enhance product performance across multiple industries.
For more information, please visit www.dyadic.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding Dyadic’s expectations, strategies, and future plans. Actual results may differ materially due to various factors, including those outlined in Dyadic’s latest SEC filings. Dyadic assumes no obligation to publicly update any forward-looking statements, whether due to new information or future events. For a comprehensive list of risks, please see the “Risk Factors” section of Dyadic’s SEC filings.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: [email protected]
